Results 81 to 90 of about 35,539 (289)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Human Vaccines & Immunotherapeutics, 2017
One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]).
Andrea A. Berry, R. Abu-Elyazeed, Clemente Díaz-Pérez, M. Mufson, C. Harrison, M. Leonardi, Jerry D Twiggs, Christopher Peltier, S. Grogg, A. Carbayo, S. Shapiro, M. Povey, C. Baccarini, B. Innis, Ouzama Henry   +14 more
semanticscholar   +1 more source

Vaccine Myths: Setting the Record Straight [PDF]

, 2018
Despite their standing as one of the most remarkable public health achievements, vaccines have been surrounded by dangerous myths since the development of the smallpox vaccine in the 18th century.
Boom, Julie A, Cunningham, Rachel M, McGee, Lindy U.   +2 more
core   +1 more source

Immunity against measles, mumps, rubella, and varicella among homeless individuals in Germany — A nationwide multi-center cross-sectional study

Frontiers in Public Health
IntroductionHomeless individuals suffer a high burden of vaccine-preventable infectious diseases. Moreover, they are particularly susceptible to adverse infection outcomes with limited access to the health care system.
Wiebke Graf, Franziska Bertram, Katharina Dost, Anna Brennecke, Veronika Kowalski, Victoria van Rüth, Dominik Sebastian Nörz, Birgit Wulff, Benjamin Ondruschka, Klaus Püschel, Susanne Pfefferle, Marc Lütgehetmann, Fabian Heinrich, Fabian Heinrich, Fabian Heinrich   +14 more
doaj   +1 more source

Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial

Human Vaccines & Immunotherapeutics, 2017
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine ...
Ashwani Sood, Monjori Mitra, Himanshu Arvind Joshi, Uma Siddhartha Nayak, Prashanth Siddaiah, T. Ramesh Babu, Samarendra Mahapatro, Jayesh Sanmukhani, Gaurav Gupta, Ravindra Mittal, Reinhard Glueck   +10 more
doaj   +1 more source

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis [PDF]

, 2016
Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance.
Casuccio, Alessandra, Costantino, Claudio, Cracchiolo, Manuela, Marchese, Valentina, Napoli, Giuseppe, on behalf of the ESCULAPIO working group,, Tabacchi, Garden, Vitale, Francesco   +7 more
core   +2 more sources

Evolution of Aluminium Sensitisation in a French Paediatric Population

Contact Dermatitis, EarlyView.
Laux Miranda, Letertre‐lelou Oriane, Naimi Nour, Segretin Pierre, Labrèze Christine, Milpied Brigitte   +5 more
wiley   +1 more source

Tuberculosis Trends in the Post‐COVID‐19 Era: Is It Going to be a Global Concern?

Health Science Reports, Volume 8, Issue 5, May 2025.
ABSTRACT Background and Aims Tuberculosis (TB), a leading cause of death from infectious diseases, faced considerable challenges during the coronavirus disease 2019 (COVID‐19) pandemic. This review examines the impact of pandemic‐related disruptions, including the diversion of healthcare resources, reduced access to TB diagnostics and treatment, and ...
Soroush Khojasteh‐Kaffash, Adrina Habibzadeh, Sina Moghaddam, Fatemeh Afra, Noosha Samieefar, Abolfazl Fateh   +5 more
wiley   +1 more source

Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.

PLoS ONE, 2014
BackgroundThe reported coverage of the measles-rubella (MR) or measles-mumps-rubella (MMR) vaccine is greater than 99.0% in Zhejiang province. However, the incidence of measles, mumps, and rubella remains high.
Zhifang Wang, Rui Yan, Hanqing He, Qian Li, Guohua Chen, Shengxu Yang, Enfu Chen   +6 more
doaj   +1 more source

Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

Journal of Infectious Diseases, 2009
BACKGROUND Since 1990, most US schoolchildren have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry. The objective of the present study was to evaluate the short- and long-term mumps immunogenicity of MMR2.
C. Lebaron, B. Forghani, C. Beck, Cedric J. Brown, D. Bi, C. Cossen, B. Sullivan   +6 more
semanticscholar   +1 more source

Exploring the Role of Pattern Recognition Receptors as Immunostimulatory Molecules

Immunity, Inflammation and Disease, Volume 13, Issue 5, May 2025.
This mini‐review summarizes different classes of pattern recognition receptors (PRRs) and the role of their agonizts that have been identified and also outlines the role of PRR ligands as immunostimulatory molecules. Overall, the mini‐review has elaborated on the role of PRRs in the development of therapeutic vaccine adjuvants.
Meenal Sharma, Priyanka Wagh, Tanvi Shinde, Diptee Trimbake, Anuradha S. Tripathy   +4 more
wiley   +1 more source